CDC and Alabama Department of Public Health (ADPH) Health Advisory

COVID 19 Rebound after Paxlovid Treatment

On Tuesday, May 24, 2022, the CDC issued a Health Alert Network (HAN) Health Advisory regarding COVID 19 rebound after Paxlovid treatment. ADPH is providing the link below, which contains important information on COVID 19 rebound, along with information regarding re isolation, and helpful tools related to eligibility and prescribing of Paxlovid.

Paxlovid continues to be recommended for early-stage treatment of mild to moderate COVID-19 among eligible persons at high risk for progression to severe disease. Paxlovid treatment helps prevent hospitalization and death due to COVID-19.

COVID-19 rebound has been reported to occur between 2 and 8 days after initial recovery and is characterized by a recurrence of COVID-19 symptoms or a new positive viral test after having tested negative. A brief return of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status. Limited information currently available from case reports suggests that persons treated with Paxlovid who experience COVID-19 rebound have had mild illness; there are no reports of severe disease. There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected.

The CDC has asked that healthcare providers advise people with COVID-19 rebound to follow CDC’s guidance on isolation and take precautions to prevent further transmission. Patients should re-isolate for at least 5 days. Per CDC guidance, they can end their re-isolation period after 5 full days if fever has resolved for 24 hours (without the use of fever-reducing medication) and symptoms are improving. The patient should wear a mask for a total of 10 days after rebound symptoms started.

Staying up to date with COVID-19 vaccination lowers the risk of getting COVID-19 and helps prevent serious outcomes of COVID-19, such as severe illness, hospitalization, and death.

For the full text of the CDC HAN see:

https://emergency.cdc.gov/han/2022/han00467.asp